Drug Discovery

Can Ianalumab Anchor Novartis’ Next Growth Cycle as Patent Pressures Mount?

23 Jan 2026 Executive Summary Novartis has secured Breakthrough Therapy designation for ianalumab, a late-stage immunology asset, reinforcing…

ByByAnuja Singh Jan 23, 2026

Can AI Become the Backbone of Global Health Equity? Gates Foundation and OpenAI Launch $50 Million Horizon1000 Initiative in Africa

Executive Summary The Bill & Melinda Gates Foundation and OpenAI have announced a $50 million public–private initiative, Horizon1000,…

ByByAnuja Singh Jan 23, 2026

Is AI Becoming Big Pharma’s Frontline Tool for Early Cancer Detection? Bristol Myers Squibb and Microsoft Signal a Strategic Shift

Executive Summary Bristol Myers Squibb (BMS) has entered a strategic partnership with Microsoft to advance AI-driven early detection…

ByByAnuja Singh Jan 23, 2026

Is JPM 2026 the Moment Biopharma Finally Reset Its Strategy?

January 2026 — San Francisco | Global — The 44th Annual J.P. Morgan Healthcare Conference (JPM 2026) marked…

ByByAnuja Singh Jan 23, 2026
Image Not Found

Atrium Therapeutics Spins Out with $270M Cash from Avidity—Preclinical AOCs Target Rare Genetic Cardiomyopathies

Published by BioNextAI Media – Atrium Therapeutics (Nasdaq: ATRM) launched as an independent public company following Novartis’ $12 billion…

ByByAnuja Singh Mar 2, 2026

Azitra Spotlights ATR-12 Phase 1b Data at BIO Summit Miami—50% Enrollment Safety Win Signals Microbiome Biotech Fundraising Surge

Published by BioNextAI Media – Azitra, Inc. (NYSE American: AZTR) takes center stage at the BIO Investment & Growth…

ByByAnuja Singh Mar 2, 2026
Scroll to Top